by goldfishadmin | Jun 17, 2013 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, presented a late-breaking poster describing the effect of antagonists to steroidogenic factor-1 (SF-1) on adrenal synthesis of glucocorticoids at the Endocrine Society’s 95th Annual Meeting in...
by goldfishadmin | May 28, 2013 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded the company $446,635 under the Small Business Innovative Research...
by goldfishadmin | Mar 5, 2013 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that it has been awarded US patent 8,389,739 for modulators of retinoid-related orphan receptor gamma (RORγ). The patent is Orphagen’s first in the RORγ field and describes several...
by goldfishadmin | Jan 8, 2013 | News
Orphagen Pharmaceuticals announced today that Gönül Veliçelebi, Founder and CEO of CalciMedica, has been appointed to the Board of Directors. “Dr. Veliçelebi’s extensive experience in drug discovery and development, entrepreneurism and corporate strategy will be...
by goldfishadmin | May 22, 2012 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, was recently profiled on the front page of BioWorld Today. A featured article on Orphagen Pharmaceuticals, titled “Orphagen Seeks Ligands for Orphan Nuclear Receptors”, highlighted the...
by goldfishadmin | Feb 7, 2012 | News
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, announced today that the National Institutes of Health has awarded the Company $220,839 in funding through the Small Business Innovative Research (SBIR) program. The Phase I grant is designed...
